Introduction: the history of arsenic trioxide in cancer therapy.
about
Arsenic trioxide for the treatment of acute promyelocytic leukaemiaHeavy metals and living systems: An overviewArsenic exposure and toxicology: a historical perspectiveThe elements of life and medicinesEnhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism.Activation of stress response pathways promotes formation of antiviral granules and restricts virus replicationRecent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancersEnhancement of arsenic trioxide-mediated changes in human induced pluripotent stem cells (IPS)Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cellsAcute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer.Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains.A broad view of arsenic.Induction of Apoptosis in the Rat Bone Marrow Mesenchymal Stem Cells Following Sodium Arsenite Treatment with the Dose Lesser than that Used for Treatment of Malignant Patient.Rapid reduction in breast cancer mortality with inorganic arsenic in drinking waterArsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview).Top five medical innovations in China mainland since Xinhai revolution [1911]: results of AME survey-002.Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells.Identification of an S-adenosylmethionine (SAM) dependent arsenic methyltransferase in Danio rerio.Arsenic-induced biochemical and genotoxic effects and distribution in tissues of Sprague-Dawley ratsDetermination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometryArsenite-induced mitotic death involves stress response and is independent of tubulin polymerization.Arsenic trioxide inhibits cancer stem-like cells via down-regulation of Gli1 in lung cancer.Arsenic-based antineoplastic drugs and their mechanisms of action.Dose- and time-dependent response of human leukemia (HL-60) cells to arsenic trioxide treatment.Darinaparsin: a novel organic arsenical with promising anticancer activity.Anticancer drugs from traditional toxic Chinese medicines.The evolving use of arsenic in pharmacotherapy of malignant disease.The role of PML in hematopoietic and leukemic stem cell maintenance.Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.Targeting PI3K/AKT/mTOR network for treatment of leukemia.Disruption of Mitotic Progression by Arsenic.What has been overlooked on study of Chinese materia medica in the West?Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma.Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.Molecular insight of arsenic-induced carcinogenesis and its prevention.Anticancer effect of arsenic trioxide on cholangiocarcinoma: in vitro experiments and in vivo xenograft mouse model.Arsenic trioxide toxicity in H9c2 myoblasts--damage to cell organelles and possible amelioration with Boerhavia diffusa.On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia
P2860
Q24239914-74498A7A-72C1-4518-A577-C46905B0499FQ24615795-EB3DBD67-3BA6-46CD-9680-BEBF2E3330A6Q28392204-21D3FEE3-1CC6-4B79-97C0-33B867CE1A5FQ28649323-BD0310A0-FD3B-4D25-8F30-DEC0BAFBC828Q33470967-9C1F2240-6EB8-4274-9C26-B99975BF9767Q33602629-EE0AE400-E61E-44D3-BFFC-B0B3A21F035FQ33768666-E8B1201D-A2E8-44C2-BDDF-1B0C187A8C16Q33964014-6197BF44-0EBA-4C60-8911-6504D837977EQ34171130-0CD27C25-BEAE-420D-A69F-FCE4A8961B50Q34267886-5ADCCB64-4D36-4D06-B5E1-6DD74F7DFCBCQ34397561-83FA8680-7B04-4A6E-9897-02CE9055E655Q34591697-14EFF0EE-C98F-4C49-AAC4-7078DDAC743DQ34592945-9D181CA5-2B34-4429-810C-27902882C75FQ34620647-604A4AC2-21D1-4450-B7BC-A11E142603C4Q34866709-D212F10C-B222-460F-8127-7307904455D5Q35155855-B1CF6EF5-85BB-4C19-AB27-E38AE874DAA9Q35589141-0F9E11AD-92AB-4C24-B7CA-F0568E45FD73Q35618400-4DD23B28-8BEB-43C3-9292-68B172D76BB4Q36088753-C957A317-C465-490C-AC52-BB287A8A2D86Q36407466-E2F4379B-6944-4FB9-A42F-8BCD71B700FCQ36566386-631A92E2-6CC1-4DD7-A190-C4C12066CDB6Q36824250-D6E16C57-C874-40AE-8423-76540975C4B3Q36841351-79AAEBC7-9969-4BA7-8164-8B13C2A5C3A4Q37145891-17AEE18B-4C0A-4DCC-96CE-31C7ADA11FB1Q37253194-0717DAAC-78AE-458C-9F86-FF5D8D4AC083Q37603342-5A2C71B1-C57C-40DE-A0EE-4AFAB507F6E3Q37990470-E9D21CB2-770F-40E5-B098-C49EA7D2B7D1Q38089629-1FBD8FE3-7003-419A-A9A5-4D2810EE9894Q38184494-A21EDC13-414C-4838-9F14-5EEFC67B9243Q38311168-CDAC3495-CDB3-458A-ADD6-0724369378C5Q38364871-150B0E9A-9BDB-4319-BC52-81DD55EAB87CQ38386478-B5713CBD-F725-4FB0-9C5A-C69087016252Q38544110-A186F29A-6181-426E-8D43-9F907969E335Q38956949-86C98587-0023-453D-A5C5-52DB74190ADAQ39036566-67F83FD2-FF17-4B8C-9D8E-16E644A1E9C6Q39120817-574E69AC-02FA-447B-8413-0B93B5414D76Q39147365-5598A222-26B4-4278-82AD-058AA805386CQ39184202-29A62035-37E4-4793-A1CF-24FD7465B49BQ39243034-9F30B699-AE96-4986-903F-981DB7A35A7BQ39276978-337D00CC-F872-4BCA-8BE6-EC7827EFE5F0
P2860
Introduction: the history of arsenic trioxide in cancer therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Introduction: the history of arsenic trioxide in cancer therapy.
@ast
Introduction: the history of arsenic trioxide in cancer therapy.
@en
type
label
Introduction: the history of arsenic trioxide in cancer therapy.
@ast
Introduction: the history of arsenic trioxide in cancer therapy.
@en
prefLabel
Introduction: the history of arsenic trioxide in cancer therapy.
@ast
Introduction: the history of arsenic trioxide in cancer therapy.
@en
P1433
P1476
Introduction: the history of arsenic trioxide in cancer therapy
@en
P2093
P356
10.1634/THEONCOLOGIST.6-SUPPL_2-1
P478
P50
P577
2001-01-01T00:00:00Z